Developer docs
API playgroundTry for free, no card

Search company profiles

CellKey

Full company profile

uuid000cogo

Namestring
CellKey
Legal namestring
(주)셀키에이아이
Websiteurl
cellkey.co.kr
Company typeenum
Private
Founded yearint
2019
Descriptiontext

CellKey AI Inc. (주식회사 셀키에이아이) is a South Korea-based biotech company founded in May 2019 and headquartered in the Osong Bio Cluster in Cheongju, with additional offices in Seoul and Torrance, California. The company builds an AI-driven multiomics analysis platform — anchored by the SpAC9 Data Foundry (a cloud-based SaaS platform for proteomics, glycoproteomics, and metabolomics data) and the proprietary One-Stop glycopeptide analysis technology, which processes glycoproteins as a unified entity and is claimed to deliver up to 100x faster analysis and 50% lower cost versus conventional methods. Its product portfolio also includes the SpAC9 AI Platform for DDA/DIA data analysis, BioEOS (a bio-vertical AI agent for R&D workflow automation), an LLM-based Multiomics AI Agent in co-development, and an AI-nanoplasmonic early liver cancer diagnostic device under joint development with Harvard MGH. The company achieved 99% accuracy at the 2019 HGI Glycopeptide Analysis Competition and holds GMP certification for its liver cancer early diagnostic product.

CellKey monetizes through a hybrid model combining professional services (multiomics analysis, biomarker co-development, companion diagnostics R&D for pharmaceutical, biotech, and academic customers) with a recurring SaaS revenue stream via the SpAC9 Data Foundry, which launched a freemium trial campaign in mid-2025. Enterprise customers include major Korean pharmaceutical and biotech companies, Korean university hospitals, and international collaborators including Harvard MGH, University College London, and Weill Cornell Medicine-Qatar Center. Go-to-market is sales-led enterprise field sales supplemented by partnership-driven co-development (D&T&C&R&O, MegazoneCloud, Charparral Labs, Protium Science, Molecular Design Research Center) and government-recognized designations (Innovative Product, Excellent Corporate Research Lab) that support public procurement and regulatory progression.

The company is led by founder-CEO Lee Nam-yong (formerly a software engineer at Samsung Electronics, Korea AWS, and Microsoft), supported by COO Lee Sang-yong and Bioinformatics Research Institute Director Park Geon-wook. CellKey has raised a Series A from D&T&C&R&O (March 2024) alongside earlier rounds from D3 Jubilee, Riga Investment, and ETRI Holdings, and was selected for Korea's Super Gap Startup 1000+ program in 2025. The firm is positioned as the only glycoproteomics-specialized company in Korea and one of only two globally, with active global expansion into the US, Japan, the Middle East, and Europe.

Short descriptiontext

CellKey AI is a South Korean biotech that builds an AI-powered multiomics and glycoproteomics analysis platform (SpAC9 Data Foundry, BioEOS) serving pharmaceutical, biotech, hospital, and academic customers for drug development, biomarker discovery, and early cancer diagnostics, with global expansion into the US, Japan, and the Middle East.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCheongju, South Korea
HQ citystring
Cheongju
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
multiomics analysis platform, proteomics data analysis, glycoprotein biomarker discovery, cloud bioinformatics software, precision medicine AI
Industry4 codes
PRIMARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGANAI
Bioinformatics, Multi-Omics Data Analysis & Interpretation Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAAANAF
Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics)
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Medical and Diagnostic Laboratories62151
  • Computer Systems Design and Related Services54151
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Bioinformatics Software
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model5 records
1Multiomics Analysis Services
TypeProfessional Services
Description

Provides high-resolution mass spectrometry-based proteomics, glycoproteomics, and metabolomics analysis services to pharmaceutical companies, biotech firms, research institutes, and hospitals. Services include antibody-drug and ADC analysis for new drug development, as well as food and environmental sample analysis.

cellkey.co.kr
2SpAC9 Data Foundry SaaS Platform
TypeSubscription Recurring
Description

Cloud-based SaaS platform subscription for multiomics data analysis with 100 credits (33GB) free trial for 30 days. Platform provides DDA/DIA search, re-search, re-analysis, and DEP reselection capabilities without batch effects.

cellkey.co.kr
3Biomarker Development Services
TypeProfessional Services
Description

Collaborative research services with hospitals and pharmaceutical companies for clinical sample-based multiomics data analysis to develop early disease diagnosis and drug response prediction biomarkers.

cellkey.co.kr
4Companion Diagnostics R&D
TypeProfessional Services
Description

R&D services for drug development companies focused on companion diagnostics development based on multiomics analysis.

cellkey.co.kr
5Global Glycoprotein Analysis Services
TypeProfessional Services
Description

International expansion of glycoprotein analysis services to US, Middle East, Europe, and Japan markets. Services include liver cancer early diagnosis product (GMP certified) and lung cancer early diagnosis products.

cellkey.co.kr
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Pricing details2 tiers
1Free Trial - 100 credits (33GB)
ModelFreemiumBilling cadencePay-as-you-go
Notes

Campaign period: July 1 - December 31, 2025. Includes unlimited access to all premium features including DDA/DIA Search, Re-Search, Re-Analysis, and DEP Reselection. After 30-day trial ends, no automatic payment occurs.

cellkey.co.kr
2Enterprise/Custom Pricing
ModelSubscriptionBilling cadenceAnnual
Notes

Custom pricing based on volume and specific service requirements for pharmaceutical companies and biotech firms. Consultation-based pricing model.

cellkey.co.kr
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 3 records shown
1SpAC9 Data Foundry
Description

AI-powered cloud-based SaaS platform for multiomics data analysis without batch effect, processing LC-MS/MS and multiomics data

cellkey.co.kr
+2 more records
Core offering1 text field

CellKey provides an AI-driven multiomics analysis platform (SpAC9 Data Foundry) and bio-vertical AI agent (BioEOS) that deliver glycoprotein, proteomics, and metabolomics analysis for pharmaceutical, biotech, hospital, and research institution customers. The company also offers professional multiomics analysis services, biomarker discovery for early disease diagnosis (liver cancer, lung cancer), and companion diagnostics R&D support. Its proprietary One-Stop glycoprotein analysis technology enables unified analysis of glycoproteins, achieving up to 100x faster processing and over 50% cost reduction versus traditional methods.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Up to 100x faster analysis speed with SpAC9 Data Foundry compared to CPU-based solutions
+3 more records
Product overview1 text field

CellKey offers a unified platform-plus-services portfolio anchored by the SpAC9 Data Foundry, a cloud-based SaaS multiomics analysis platform, complemented by the BioEOS bio-vertical AI agent and an LLM-based Multiomics AI Agent. These core AI-driven platforms are delivered alongside two service lines: Multiomics Services (high-resolution mass spectrometry-based proteomics, glycoproteomics, and metabolomics analysis) and Biomarker Services (clinical sample-based AI-powered biomarker discovery for early disease diagnosis). The company also develops a CDMO AI optimization solution for biopharmaceutical manufacturing and an AI-nanoplasmonic early liver cancer diagnostic device in partnership with Harvard MGH.

Product and service3 records
1SpAC9 Data Foundry (스팩9 데이터 파운드리)
CategoryBioinformatics Software / SaaS Platform
Description

Cloud-based SaaS multiomics analysis platform that processes LC-MS/MS and multiomics data (proteomics, glycoproteomics, metabolomics) with batch-effect-free standardization across hundreds to thousands of samples. Offers DDA/DIA Search, Re-Search, Re-Analysis, and DEP Reselection capabilities at up to 100x faster analysis speed than CPU-based solutions, with biological functional analysis integration to GO, KEGG, Pfam, Reactome, InterPro, Phosida, and STRING databases.

2BioEOS (바이오이오스)
CategoryAI Agent / Vertical AI Software
Description

Bio-vertical AI agent that precisely analyzes and automates bio data and workflows using AI, providing biological insights to support R&D decision-making for pharmaceutical and biotech companies. Analyzes multimodal data including omics, EMR (electronic medical records), and pathology images, and integrates AI agents for scientific evidence search and research report automation.

3Multiomics Analysis Services
Scale indicator8 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers3 records
TypeDirect peer
Description

US proteomics platform company combining proprietary sample preparation with AI-driven analysis of large-scale proteomic datasets for biomarker discovery. Closely comparable to CellKey in offering an integrated platform-and-services proteomics offering to pharma/biotech.

TypeDirect peer
TypeDirect peer
Description

US-based glycoproteomics company explicitly cited in CellKey's own materials as one of only two companies globally (alongside CellKey) utilizing glycoprotein technology for diagnostics. Most directly comparable peer in glycoproteomics-based diagnostic applications.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration7 records

Each record includes

Title, Type, Description, Source

AI capability7 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

CellKey

Bioinformatics Softwarecellkey.co.kr

CellKey AI is a South Korean biotech that builds an AI-powered multiomics and glycoproteomics analysis platform (SpAC9 Data Foundry, BioEOS) serving pharmaceutical, biotech, hospital, and academic customers for drug development, biomarker discovery, and early cancer diagnostics, with global expansion into the US, Japan, and the Middle East.

What CellKey does

CellKey AI Inc. (주식회사 셀키에이아이) is a South Korea-based biotech company founded in May 2019 and headquartered in the Osong Bio Cluster in Cheongju, with additional offices in Seoul and Torrance, California. The company builds an AI-driven multiomics analysis platform — anchored by the SpAC9 Data Foundry (a cloud-based SaaS platform for proteomics, glycoproteomics, and metabolomics data) and the proprietary One-Stop glycopeptide analysis technology, which processes glycoproteins as a unified entity and is claimed to deliver up to 100x faster analysis and 50% lower cost versus conventional methods. Its product portfolio also includes the SpAC9 AI Platform for DDA/DIA data analysis, BioEOS (a bio-vertical AI agent for R&D workflow automation), an LLM-based Multiomics AI Agent in co-development, and an AI-nanoplasmonic early liver cancer diagnostic device under joint development with Harvard MGH. The company achieved 99% accuracy at the 2019 HGI Glycopeptide Analysis Competition and holds GMP certification for its liver cancer early diagnostic product.

CellKey monetizes through a hybrid model combining professional services (multiomics analysis, biomarker co-development, companion diagnostics R&D for pharmaceutical, biotech, and academic customers) with a recurring SaaS revenue stream via the SpAC9 Data Foundry, which launched a freemium trial campaign in mid-2025. Enterprise customers include major Korean pharmaceutical and biotech companies, Korean university hospitals, and international collaborators including Harvard MGH, University College London, and Weill Cornell Medicine-Qatar Center. Go-to-market is sales-led enterprise field sales supplemented by partnership-driven co-development (D&T&C&R&O, MegazoneCloud, Charparral Labs, Protium Science, Molecular Design Research Center) and government-recognized designations (Innovative Product, Excellent Corporate Research Lab) that support public procurement and regulatory progression.

The company is led by founder-CEO Lee Nam-yong (formerly a software engineer at Samsung Electronics, Korea AWS, and Microsoft), supported by COO Lee Sang-yong and Bioinformatics Research Institute Director Park Geon-wook. CellKey has raised a Series A from D&T&C&R&O (March 2024) alongside earlier rounds from D3 Jubilee, Riga Investment, and ETRI Holdings, and was selected for Korea's Super Gap Startup 1000+ program in 2025. The firm is positioned as the only glycoproteomics-specialized company in Korea and one of only two globally, with active global expansion into the US, Japan, the Middle East, and Europe.

CellKey firmographics

Firmographics
Name
CellKey
Legal name
(주)셀키에이아이
Website
https://cellkey.co.kr
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
11–50 employees
Short description
CellKey AI is a South Korean biotech that builds an AI-powered multiomics and glycoproteomics analysis platform (SpAC9 Data Foundry, BioEOS) serving pharmaceutical, biotech, hospital, and academic customers for drug development, biomarker discovery, and early cancer diagnostics, with global expansion into the US, Japan, and the Middle East.
Ownership category
akta.pro rank

CellKey industry classification

Industry
Product category
Bioinformatics Software
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical and Diagnostic Laboratories (62151), Computer Systems Design and Related Services (54151)
SIC
Services-Commercial Physical & Biological Research (8731), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGANAI
Bioinformatics, Multi-Omics Data Analysis & Interpretation Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAAANAF
Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics)

Keywords

  • Multiomics analysis platform
  • Proteomics data analysis
  • Glycoprotein biomarker discovery
  • Cloud bioinformatics software
  • Precision medicine AI

Where CellKey is headquartered

Location

Headquarters

HQ city
Cheongju
HQ country
South Korea
HQ region
Asia

Offices2 records

Markets served

CellKey business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Multiomics Analysis Services: Provides high-resolution mass spectrometry-based proteomics, glycoproteomics, and metabolomics analysis services to pharmaceutical companies, biotech firms, research institutes, and hospitals. Services include antibody-drug and ADC analysis for new drug development, as well as food and environmental sample analysis.
  2. SpAC9 Data Foundry SaaS Platform: Cloud-based SaaS platform subscription for multiomics data analysis with 100 credits (33GB) free trial for 30 days. Platform provides DDA/DIA search, re-search, re-analysis, and DEP reselection capabilities without batch effects.
  3. Biomarker Development Services: Collaborative research services with hospitals and pharmaceutical companies for clinical sample-based multiomics data analysis to develop early disease diagnosis and drug response prediction biomarkers.
  4. Companion Diagnostics R&D: R&D services for drug development companies focused on companion diagnostics development based on multiomics analysis.
  5. Global Glycoprotein Analysis Services: International expansion of glycoprotein analysis services to US, Middle East, Europe, and Japan markets. Services include liver cancer early diagnosis product (GMP certified) and lung cancer early diagnosis products.

Pricing tiers

ModelBillingPrice
FreemiumPay-as-you-goFree Trial - 100 credits (33GB)
SubscriptionAnnualEnterprise/Custom Pricing

Go-to-market motion2 records

Distribution channels5 records

Marketing channels7 records

CellKey product offering

Product offering

Core offering

CellKey provides an AI-driven multiomics analysis platform (SpAC9 Data Foundry) and bio-vertical AI agent (BioEOS) that deliver glycoprotein, proteomics, and metabolomics analysis for pharmaceutical, biotech, hospital, and research institution customers. The company also offers professional multiomics analysis services, biomarker discovery for early disease diagnosis (liver cancer, lung cancer), and companion diagnostics R&D support. Its proprietary One-Stop glycoprotein analysis technology enables unified analysis of glycoproteins, achieving up to 100x faster processing and over 50% cost reduction versus traditional methods.

Product overview

CellKey offers a unified platform-plus-services portfolio anchored by the SpAC9 Data Foundry, a cloud-based SaaS multiomics analysis platform, complemented by the BioEOS bio-vertical AI agent and an LLM-based Multiomics AI Agent. These core AI-driven platforms are delivered alongside two service lines: Multiomics Services (high-resolution mass spectrometry-based proteomics, glycoproteomics, and metabolomics analysis) and Biomarker Services (clinical sample-based AI-powered biomarker discovery for early disease diagnosis). The company also develops a CDMO AI optimization solution for biopharmaceutical manufacturing and an AI-nanoplasmonic early liver cancer diagnostic device in partnership with Harvard MGH.

Differentiator

Problem solved

Functional benefit

Brands

  • SpAC9 Data Foundry: AI-powered cloud-based SaaS platform for multiomics data analysis without batch effect, processing LC-MS/MS and multiomics data
  • BioEOS
  • SpAC9 AI Platform

Products and services

  • SpAC9 Data Foundry (스팩9 데이터 파운드리) Cloud-based SaaS multiomics analysis platform that processes LC-MS/MS and multiomics data (proteomics, glycoproteomics, metabolomics) with batch-effect-free standardization across hundreds to thousands of samples. Offers DDA/DIA Search, Re-Search, Re-Analysis, and DEP Reselection capabilities at up to 100x faster analysis speed than CPU-based solutions, with biological functional analysis integration to GO, KEGG, Pfam, Reactome, InterPro, Phosida, and STRING databases.
  • BioEOS (바이오이오스) Bio-vertical AI agent that precisely analyzes and automates bio data and workflows using AI, providing biological insights to support R&D decision-making for pharmaceutical and biotech companies. Analyzes multimodal data including omics, EMR (electronic medical records), and pathology images, and integrates AI agents for scientific evidence search and research report automation.
  • Multiomics Analysis Services

Quantifiable outcome

  • Up to 100x faster analysis speed with SpAC9 Data Foundry compared to CPU-based solutions
  • +3 more outcomes

Companies that use CellKey

Customer profile

Named customers6 records

Segments4 records

Ideal customer profiles3 records

CellKey technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration7 records

AI capability7 records

Feature7 records

CellKey partnerships and signals

Strategic signal

Scale indicators8 records

Recent moves6 records

Expansion highlights7 records

CellKey competitors and assessment

Company assessment

Direct peers

  • Seer: US proteomics platform company combining proprietary sample preparation with AI-driven analysis of large-scale proteomic datasets for biomarker discovery. Closely comparable to CellKey in offering an integrated platform-and-services proteomics offering to pharma/biotech.
  • Nautilus Biotechnology:
  • Interven Biosciences: US-based glycoproteomics company explicitly cited in CellKey's own materials as one of only two companies globally (alongside CellKey) utilizing glycoprotein technology for diagnostics. Most directly comparable peer in glycoproteomics-based diagnostic applications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

CellKey social profiles

Digital presence

CellKey compliance and trust

Trust signal

Compliance3 records

CellKey financial estimates

Financial estimate

Revenue estimate

Valuation estimate

CellKey leadership team

Management profile

Number of profiles

Profiles3 records

CellKey funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

CellKey M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CellKey

What does CellKey do?

CellKey provides an AI-driven multiomics analysis platform (SpAC9 Data Foundry) and bio-vertical AI agent (BioEOS) that deliver glycoprotein, proteomics, and metabolomics analysis for pharmaceutical, biotech, hospital, and research institution customers. The company also offers professional multiomics analysis services, biomarker discovery for early disease diagnosis (liver cancer, lung cancer), and companion diagnostics R&D support. Its proprietary One-Stop glycoprotein analysis technology enables unified analysis of glycoproteins, achieving up to 100x faster processing and over 50% cost reduction versus traditional methods.

Is CellKey a public or private company?

CellKey is a private company. It is classified as venture growth investor backed and is currently operating.

When was CellKey founded?

CellKey was founded in 2019. It employs 11 to 50 people.

Where is CellKey based?

CellKey is headquartered in Cheongju, South Korea, in the Asia region.

How does CellKey make money?

Five revenue lines are on record. Multiomics Analysis Services are the primary driver. The others are spAC9 Data Foundry SaaS Platform, biomarker Development Services, companion Diagnostics R&D and global Glycoprotein Analysis Services.

Who are CellKey's main competitors?

Direct peers on record are Seer, Nautilus Biotechnology and Interven Biosciences.

Does CellKey have an API?

No public API is recorded for CellKey.

What industry is CellKey in?

CellKey's product category is Bioinformatics Software. Its primary akta.pro industry code is HLAGAJAD, Bioinformatics & Multi-omics Analysis Software, with a secondary code of HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization. Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals